ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AEZS Aeterna Zentaris Inc

1.9562
-0.0038 (-0.19%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aeterna Zentaris Inc NASDAQ:AEZS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0038 -0.19% 1.9562 1.83 2.03 1.965 1.95 1.95 5,110 01:00:00

Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference

09/06/2017 1:30pm

Business Wire


Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Aeterna Zentaris Charts.

Aeterna Zentaris Inc. (TSX: AEZS) (NASDAQ: AEZS) (the “Company”) today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the 2017 Marcum MicroCap Conference on Friday, June 16, 2017 at 9:30 a.m. (Eastern) in New York City. A copy of the presentation will be available on the Company’s website at www.aezsinc.com.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. We are engaged in drug development activities and in the promotion of products for others. We recently completed Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Aeterna ZentarisPhilip A. Theodore, 843-900-3223Senior Vice Presidentir@aezsinc.com

1 Year Aeterna Zentaris Chart

1 Year Aeterna Zentaris Chart

1 Month Aeterna Zentaris Chart

1 Month Aeterna Zentaris Chart

Your Recent History

Delayed Upgrade Clock